80 related articles for article (PubMed ID: 36346486)
21. The influence of axillary surgery and radiotherapeutic strategy on the risk of lymphedema and upper extremity dysfunction in early breast cancer patients.
Zheng SY; Chen CY; Qi WX; Cai G; Xu C; Cai R; Qian XF; Shen KW; Cao L; Chen JY
Breast; 2023 Apr; 68():142-148. PubMed ID: 36764019
[TBL] [Abstract][Full Text] [Related]
22. Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
Zhai J; Sun X; Zhao F; Pan B; Li H; Lv Z; Cao M; Zhao J; Mo H; Ma F; Xu B
Breast; 2023 Feb; 67():36-45. PubMed ID: 36586272
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer.
Zhou S; Liu T; Kuang X; Zhen T; Shi H; Lin Y; Shao N
Breast; 2023 Feb; 67():1-7. PubMed ID: 36535072
[TBL] [Abstract][Full Text] [Related]
24. Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.
Na S; Kim M; Park Y; Kwon HJ; Shin HC; Kim EK; Jang M; Kim SM; Park SY
Breast Cancer; 2024 Apr; ():. PubMed ID: 38643429
[TBL] [Abstract][Full Text] [Related]
25. Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?
Polidorio N; Montagna G; Sevilimedu V; Le T; Morrow M
Ann Surg Oncol; 2024 Apr; 31(4):2231-2243. PubMed ID: 38158494
[TBL] [Abstract][Full Text] [Related]
26. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
27. Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis.
Li S; Yang X; Zhang Y; Fan L; Zhang F; Chen L; Zhou Y; Chen X; Jiang J
Breast Cancer Res Treat; 2012 Sep; 135(2):325-34. PubMed ID: 22527109
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.
Chen R; Qi Y; Huang Y; Liu W; Yang R; Zhao X; Wu Y; Li Q; Wang Z; Sun X; Wei B; Chen J
Breast Cancer Res Treat; 2023 Jan; 197(1):189-200. PubMed ID: 36346486
[TBL] [Abstract][Full Text] [Related]
29. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
Chen X; Yuan Y; Gu Z; Shen K
Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
[TBL] [Abstract][Full Text] [Related]
31. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.
Chen X; Sun L; Mao Y; Zhu S; Wu J; Huang O; Li Y; Chen W; Wang J; Yuan Y; Fei X; Jin X; Shen K
BMC Cancer; 2013 Aug; 13():390. PubMed ID: 23957561
[TBL] [Abstract][Full Text] [Related]
32. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
33. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
[TBL] [Abstract][Full Text] [Related]
34. DESTINY-Changing Results for Advanced Breast Cancer.
Hurvitz SA
N Engl J Med; 2022 Jul; 387(1):75-76. PubMed ID: 35793210
[No Abstract] [Full Text] [Related]
35. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
